Quality of Life in Children and Adolescents with Neurofibromatosis Type 1: A Single-Center Observational Study

Abstract

This article obtains an overview of the health status of children and adolescents with neurofibromatosis type 1 (NF1) with a focus on the clinical course of the disease, neuropsychodiagnostic findings, and their impact on quality of life (QoL). In this observational study, data were collected from 24 children and adolescents with NF1 who were cared for at the University Hospital in Innsbruck, Austria, from 2008 to 2022. Data were collected every 6 to 12 months from routine check-ups, including clinical features and imaging findings. Results of neuropsychodiagnostic tests and the KINDL questionnaire to assess QoL were included. Of 24 patients, 15 underwent a neuropsychological examination. Attention performance was examined in 11 of them. Eight of 11 (72%) showed an attention deficit. Assessment for specific developmental disorders showed visual-spatial difficulties in 12/15 (80%) patients. The KINDL questionnaire values ranged from 58.22 to 97.92 (0 stands for reduced QoL, 100 for very good QoL). Patients with scoliosis had a lower range of QoL (56.33–73.96). No trend in QoL was observed in children and adolescents with plexiform neurofibromas, below-average intelligence or optic gliomas. NF1 patients show very different clinical courses. Regular neuropsychological assessment especially with regard to visual-spatial skills and attention deficits is necessary to offer appropriate support, promote children's development, and thus improve their QoL.

Keywords

neurofibromatosis type 1 - quality of life - attention deficit - visual-spatial difficulties

Publication History

Received: 16 February 2023

Accepted: 18 April 2023

Article published online:
15 June 2023

• References

• 1 Cimino PJ, Gutmann DH. Neurofibromatosis type 1. In: Handbook of Clinical Neurology. Vol. 148. Elsevier B.V.; 2018: 799-811
• 2 Wolkenstein P, Rodriguez D, Ferkal S. et al. Impact of neurofibromatosis 1 upon quality of life in childhood: a cross-sectional study of 79 cases. Br J Dermatol 2009; 160 (04) 844-848
• 3 Lehtonen A, Howie E, Trump D, Huson SM. Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence. Dev Med Child Neurol 2013; 55 (02) 111-125
• 4 Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 2014; 13 (08) 834-843
• 5 National Institutes of Health Consensus Development Conference. Neurofibromatosis. Conference statement. Arch Neurol 1988; 45 (05) 575-578
• 6 Legius E, Messiaen L, Wolkenstein P. et al; International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC). Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 2021; 23 (08) 1506-1513
• 7 Remschmidt H. ed. 13 Klassifikation psychischer Störungen. In: Kinder- Und Jugendpsychiatrie. Stuttgart: Georg Thieme Verlag; 2011: 105-108
• 8 Ravens-Sieberer U, Bullinger M. Kindl-Manual [online document]. 2000 . Accessed March 13, 2001, at: https://www.kindl.org/app/download/6152202784/KINDL+Manual_Deutsch.pdf?t=1509452545
• 9 Miller DT, Freedenberg D, Schorry E. et al. Council on Genetics, American College of Medical Genetics and Genomics. Health supervision for children with neurofibromatosis type 1. Pediatrics 2019; 143 (05) e20190660
• 10 Hersh JH, Hersh JH. American Academy of Pediatrics Committee on Genetics. Health supervision for children with neurofibromatosis. Pediatrics 2008; 121 (03) 633-642
• 11 Nupan MMT, Van Meerbeke AV, Cabra CAL, Gomez PMH. Cognitive and behavioral disorders in children with neurofibromatosis type 1. Front Pediatr 2017; 5: 227
• 12 Payne JM, Barton B, Shores EA, North KN. Paired associate learning in children with neurofibromatosis type 1: implications for clinical trials. J Neurol 2013; 260 (01) 214-220
• 13 Graf A, Landolt MA, Mori AC, Boltshauser E. Quality of life and psychological adjustment in children and adolescents with neurofibromatosis type 1. J Pediatr 2006; 149 (03) 348-353
• 14 Krab LC, Oostenbrink R, de Goede-Bolder A, Aarsen FK, Elgersma Y, Moll HA. Health-related quality of life in children with neurofibromatosis type 1: contribution of demographic factors, disease-related factors, and behavior. J Pediatr 2009; 154 (03) 420-425 , 425.e1
• 15 Cipolletta S, Spina G, Spoto A. Psychosocial functioning, self-image, and quality of life in children and adolescents with neurofibromatosis type 1. Child Care Health Dev 2018; 44 (02) 260-268